Bangyun Medical secures nearly RMB 100 million angel round for high-end wound closure upgrades and global innovation

Recently, Bangyun Medical announced the completion of nearly 100 million RMB in angel round financing. This financing round was led by Dalton Venture, with participation from Jinding Capital. The proceeds will be primarily used for: expanding production capacity for high-end products such as absorbable barbed sutures and antibacterial sutures, as well as tackling the development of an independent domestic supply chain for raw materials; the development and clinical trials of BESTURE, a world-first innovative accelerated wound healing product; and the expansion of professional sales and market operations teams.

Bangyun Medical established in 2019, focuses on the research, development, production, and sales of high-end wound closure consumables and instruments for surgical procedures. Its products cover clinical departments such as general surgery, gynecology, urology, and plastic surgery. The company is committed to providing high-quality wound closure solutions for medical professionals and patients through localized compliant manufacturing and clinically driven innovation.

Medical sutures are an indispensable product in the healthcare field, widely used in various types of surgical procedures, including open surgery, minimally invasive surgery, specialized surgeries, as well as in wartime, disaster, and trauma care scenarios. According to data from Frost & Sullivan, the Chinese surgical suture market is expected to reach a size of 8.6 billion RMB by 2026, and is projected to exceed 10 billion RMB by 2030, making it one of the largest single-product markets in the minimally invasive surgery sector. The accelerating aging of the population, steady growth in the total volume of surgical procedures, increased adoption of minimally invasive surgery, and the expansion of primary healthcare service capabilities together form the solid demand foundation for the long-term growth of this market.

Among these products, high-end functional products such as absorbable and knotless barbed sutures are leading the industry with a growth rate approximately three to four times that of traditional sutures, and their market share continues to increase. However, for a long time, over 70 percent of the high-end market share in this field has been dominated by foreign brands such as Johnson & Johnson, while Chinese domestic brands have been largely concentrated in the mid-to-low-end segments, with core technologies and supply chains long constrained by foreign players. Nevertheless, driven by four core forces—the normalization of centralized procurement, domestic technological breakthroughs in China, the upgrading of clinical demand, and the tightening of industry compliance—the medical suture market is undergoing a profound restructuring, presenting a new landscape characterized by domestic high-end market breakthroughs, a structural shift toward innovation, and competition centered on value delivery.

Against this backdrop, Bangyun Medical has achieved a breakthrough with its differentiated product portfolio. Its core product, Weijia® Absorbable Knotless Surgical Barbed Suture, requires no knot tying and is biodegradable in the body. It is suitable for tissue closure scenarios in minimally invasive surgeries such as laparoscopy, effectively shortening surgical time and reducing intraoperative bleeding. Building on this foundation, Bangyun Medical has progressed from supply chain development to independent innovation. Its proprietary triclosan-based antibacterial suture production process achieves long-term, stable drug release while meeting the same content standards as imported competitors, avoiding the clinical pain point of excessive tissue reaction. Furthermore, Bangyun Medical, in collaboration with a professor team from Donghua University, has developed BESTURE, a world-first absorbable self-powered electric suture. By generating electrical stimulation through movement, it accelerates wound healing by up to 50 percent. The relevant research findings were published in 2024 in Nature Communications, a top-tier international academic journal.

Bangyun Medical's outstanding technological innovation capability stems from its top-tier core management team and interdisciplinary research and development team. Su Jin, Chairman and General Manager, previously worked at Johnson & Johnson for 14 years and served as President of B. Braun China for 10 years, bringing deep international vision and management integration capabilities. Bangyun Medical's senior executives in production, marketing, and research and development possess backgrounds in multinational corporate management and top-tier academic experience. At the same time, supported by an interdisciplinary development team composed of doctoral supervisors, materials science PhDs, and clinical physicians, Bangyun Medical ensures end-to-end support for its products from research and development through production to commercial implementation.

Leveraging the policy opportunity presented by the national centralized volume-based procurement of medical consumables, Bangyun Medical has achieved rapid market breakthroughs. In the recent inter-provincial alliance centralized procurement for sutures, led by Liaoning Province and involving 24 provinces, municipalities, autonomous regions, and municipalities directly under the central government, all of Bangyun Medical's suture product categories were successfully selected. In the core barbed suture segment, the company ranked in the top tier, securing qualifications for secondary volume allocation and free volume distribution, covering a vast market of over 800 million people across China. This is expected to significantly enhance the market penetration and clinical accessibility of domestic high-end knotless barbed sutures in China.

Not only has Bangyun Medical achieved breakthroughs in the Chinese domestic market, but it has also gained high recognition from global medical device giant Medtronic, leveraging its proprietary production processes and ISO 13485 quality system certified by TÜV SÜD. Kandi Technology, a subsidiary of Medtronic, has officially launched a strategic collaboration project with Bangyun Medical named "Suture for Future," focusing on surgical sutures. The two parties have reached a production capacity cooperation intent at the level of millions of sutures, marking Bangyun Medical's official entry into a new phase of international collaborative innovation and signaling the gradual entry of Chinese domestic high-end sutures into the global market.